Hu L - Search Results

1

Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model.

Hu L, Hofmann J, Holash J, Yancopoulos GD, Sood AK, Jaffe RB. Hu L, et al. Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6966-71. doi: 10.1158/1078-0432.CCR-05-0910. Clin Cancer Res. 2005. PMID: 16203789

2

Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.

Hu L, Hofmann J, Lu Y, Mills GB, Jaffe RB. Hu L, et al. Cancer Res. 2002 Feb 15;62(4):1087-92. Cancer Res. 2002. PMID: 11861387

3

Vascular endothelial growth factor immunoneutralization plus Paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer.

Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Hu L, et al. Am J Pathol. 2002 Nov;161(5):1917-24. doi: 10.1016/S0002-9440(10)64467-7. Am J Pathol. 2002. PMID: 12414537 Free PMC article.

4

Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model.

Byrne AT, Ross L, Holash J, Nakanishi M, Hu L, Hofmann JI, Yancopoulos GD, Jaffe RB. Byrne AT, et al. Among authors: hu l. Clin Cancer Res. 2003 Nov 15;9(15):5721-8. Clin Cancer Res. 2003. PMID: 14654557

5

Phosphatidylinositol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma.

Hu L, Hofmann J, Jaffe RB. Hu L, et al. Clin Cancer Res. 2005 Nov 15;11(22):8208-12. doi: 10.1158/1078-0432.CCR-05-0206. Clin Cancer Res. 2005. PMID: 16299254

6

Paracrine VEGF/VE-cadherin action on ovarian cancer permeability.

Hu L, Ferrara N, Jaffe RB. Hu L, et al. Exp Biol Med (Maywood). 2006 Nov;231(10):1646-52. doi: 10.1177/153537020623101010. Exp Biol Med (Maywood). 2006. PMID: 17060686

7

Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.

Huang J, Hu W, Hu L, Previs RA, Dalton HJ, Yang XY, Sun Y, McGuire M, Rupaimoole R, Nagaraja AS, Kang Y, Liu T, Nick AM, Jennings NB, Coleman RL, Jaffe RB, Sood AK. Huang J, et al. Among authors: hu w, hu l. Mol Cancer Ther. 2016 Jun;15(6):1344-52. doi: 10.1158/1535-7163.MCT-15-0144. Epub 2016 Mar 23. Mol Cancer Ther. 2016. PMID: 27009216 Free PMC article.

8

In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002).

Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. Hu L, et al. Clin Cancer Res. 2000 Mar;6(3):880-6. Clin Cancer Res. 2000. PMID: 10741711

9

Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant.

Hu L, McArthur C, Jaffe RB. Hu L, et al. Br J Cancer. 2010 Apr 13;102(8):1276-83. doi: 10.1038/sj.bjc.6605626. Epub 2010 Mar 30. Br J Cancer. 2010. PMID: 20354527 Free PMC article.

10

Exogenous glutamate enhances glutamate receptor subunit expression during selective neuronal injury in the ventral arcuate nucleus of postnatal mice.

Hu L, Fernstrom JD, Goldsmith PC. Hu L, et al. Neuroendocrinology. 1998 Aug;68(2):77-88. doi: 10.1159/000054353. Neuroendocrinology. 1998. PMID: 9705574

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,042 results

Search Page

Filters